Skip to content

Misoprostol for treating postpartum haemorrhage: a randomised controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN72263357
Enrollment
Unknown
Registered
2004-07-20
Start date
2002-01-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postpartum haemorrhage Pregnancy and Childbirth

Interventions

1. Intervention group: Misoprostol 200 µg tablets. Each woman receives 1 tablet orally, 2 tablets sublingually and 2 tablets rectally. 2. Control group: identical placebo tablets. Each woman receives

Sponsors

University of the Witwatersrand (South Africa)
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Women with postpartum haemorrhage defined as vaginal bleeding after childbirth considered to be excessive, and considered likely to be due to inadequate uterine contraction

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
Not provided at time of registration

Secondary

MeasureTime frame
Not provided at time of registration

Countries

South Africa

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 26, 2026